StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report released on Monday. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

Shares of BTX opened at $0.27 on Monday. The firm has a market capitalization of $15.98 million, a price-to-earnings ratio of -0.12 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 52 week low of $0.17 and a 52 week high of $10.10. The business’s fifty day moving average price is $0.78 and its two-hundred day moving average price is $1.38.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.